| Literature DB >> 32978602 |
Jianhui Nie1, Qianqian Li1,2, Jiajing Wu1,3, Chenyan Zhao1, Huan Hao1, Huan Liu1, Li Zhang1, Lingling Nie1, Haiyang Qin1, Meng Wang1, Qiong Lu1, Xiaoyu Li1, Qiyu Sun1, Junkai Liu1, Changfa Fan4, Weijin Huang5, Miao Xu6, Youchun Wang7,8.
Abstract
Pseudotyped viruses are useful virological tools because of their safety and versatility. On the basis of a vesicular stomatitis virus (VSV) pseudotyped virus production system, we developed a pseudotyped virus-based neutralization assay against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in biosafety level 2 facilities. Compared with the binding antibody test, the neutralization assay could discriminate the protective agents from the antibody family. This protocol includes production and titration of the SARS-CoV-2 S pseudotyped virus and the neutralization assay based on it. Various types of samples targeting virus attachment and entry could be evaluated for their potency, including serum samples derived from animals and humans, monoclonal antibodies and fusion inhibitors (peptides or small molecules). If the pseudotyped virus stock has been prepared in advance, it will take 2 days to get the potency data for the candidate samples. Experience in handling cells is needed before implementing this protocol.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32978602 DOI： 10.1038/s41596-020-0394-5
Source DB: PubMed Journal: Nat Protoc ISSN： 1750-2799 Impact factor: 13.491